News
CELU
0.6866
-2.01%
-0.0141
Weekly Report: what happened at CELU last week (0803-0807)?
Weekly Report · 23h ago
Celularity Announces Sudden Exit of Chief Commercial Officer
TipRanks · 3d ago
Weekly Report: what happened at CELU last week (0727-0731)?
Weekly Report · 08/03 09:58
Celularity Faces Nasdaq Listing Compliance Bid-Price Warning
TipRanks · 07/29 21:04
Weekly Report: what happened at CELU last week (0720-0724)?
Weekly Report · 07/27 10:01
Weekly Report: what happened at CELU last week (0713-0717)?
Weekly Report · 07/20 09:58
Weekly Report: what happened at CELU last week (0706-0710)?
Weekly Report · 07/13 10:00
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 07/06 21:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 07/06 17:05
Weekly Report: what happened at CELU last week (0629-0703)?
Weekly Report · 07/06 10:03
Celularity Secures Insider-Backed Short-Term Loan Facility
TipRanks · 06/30 13:41
Celularity Secures $1M Secured Loan From Philip & Daniele Barach Family Trust On June 29, 2026
Benzinga · 06/30 13:06
Weekly Report: what happened at CELU last week (0622-0626)?
Weekly Report · 06/29 09:59
Celularity Strengthens Leadership With New Executive Appointments
TipRanks · 06/25 21:48
Weekly Report: what happened at CELU last week (0615-0619)?
Weekly Report · 06/22 10:06
Penny Stocks: Why Is Celularity (CELU) Stock Trending Today?
TipRanks · 06/21 11:41
Weekly Report: what happened at CELU last week (0608-0612)?
Weekly Report · 06/15 10:07
Celularity Faces Nasdaq Listing Compliance Risk After Notice
TipRanks · 06/12 23:59
Weekly Report: what happened at CELU last week (0601-0605)?
Weekly Report · 06/08 10:04
Celularity announces cenplacel-L availability for investigational use in Florida
TipRanks · 06/04 12:20
More
Webull provides a variety of real-time CELU stock news. You can receive the latest news about Celularity Inc through multiple platforms. This information may help you make smarter investment decisions.
About CELU
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Its IMPACT manufacturing platform is a fully integrated process designed to optimize the speed of the sourcing of placentas from full-term healthy informed consent donors through the use of proprietary processing methods, cell selection, product-specific chemistry, manufacturing and control (CMC), advanced cell manufacturing and cryopreservation. It also provides contract manufacturing and development services to third parties.